Brief: Benitec Biopharma Announces First Subject Dosed In Phase 1B/2A Clinical Trial For Gene Therapy Candidate BB-301
30/11/2023 12:16
Nov 30 (Reuters) - Benitec Biopharma Inc BNTC.O :
* BENITEC BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE
1B/2A
CLINICAL TRIAL FOR GENE THERAPY CANDIDATE BB-301 FOR THE
TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY
* BENITEC BIOPHARMA INC: INTERIM SAFETY AND EFFICACY DATA
ARE
EXPECTED TO BECOME AVAILABLE FROM BB-301 PHASE 1B/2A CLINICAL
TREATMENT STUDY IN MID-2024
Source text for Eikon: ID:nGNX2tGSJN
Further company coverage: BNTC.O
((Reuters.Briefs@thomsonreuters.com;))